ByoPlanet and Merck Animal Health Announce Partnership with USEF

New collaboration to protect the health of animals through innovations in environmental infection control

ATHENS, GA, May 23, 2023– ByoPlanet, a wholly owned subsidiary of Plandai Biotechnology, Inc. (OTC PINK: PLPL), and Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), are proud to announce a groundbreaking partnership with The United States Equestrian Federation (USEF) to advance animal health through innovative products and technologies.

“We are proud to partner with USEF and ByoPlanet to showcase our cutting-edge products and further our commitment to protecting the health and welfare of animals,” said Dr. Bryant Craig, associate director of scientific affairs for equine professional services and pharmacovigilance at Merck Animal Health. “ByoPlanet’s patented technologies paired with Merck Animal Health’s leading antimicrobic products has the potential to revolutionize pathogen control in the equine industry by providing enhanced protection for horses and giving peace of mind to their caretakers.”

Byoplanet is the manufacturer of the most sophisticated electrostatic spray systems on the market. When paired together with Merck Animal Health’s robust antimicrobial solutions, ByoPlanet’s patented technologies provide a comprehensive answer to enhancing pathogen control in the animal health space.

“Our primary goal at ByoPlanet is to create a pathogen-free environment for all equine areas,” said Rick O’Shea, CEO of ByoPlanet. “Our advanced technology is designed to ensure that no surface remains untouched. In collaboration with Merck Animal Health, we are proud to drive forward innovation in technology and chemistry, all in the service of equine welfare.”

Layson Griffin, spokesperson for USEF, echoed the excitement about this collaboration. “The future of pathogen control in animal health environments is in good hands with Merck Animal Health and ByoPlanet leading the charge,” Griffin stated. “We look forward to a future where infections and diseases are a thing of the past, and our beloved animals can enjoy a brighter, healthier life.”

For more information about this ground-breaking partnership, please visit www.usef.org.

About USEF:

US Equestrian trains, selects, and funds our United States Equestrian Team, which consistently wins medals at the highest level of international competition, including the Olympic Games. US Equestrian also licenses equestrian competitions of all levels across the United States each year.

US Equestrian contributes to the greater good of horses by assisting with their protection and welfare in crisis situations and natural disasters, as well as in daily competition. As part of this pledge to protect equine welfare, US Equestrian continues to help support federal and state governments and works closely with other national equine organizations.

About ByoPlanet:

ByoPlanet, with a mission dedicated to enhancing indoor air quality, is a leader in disinfection solutions, providing innovative technologies and services that improve health outcomes in a variety of settings. ByoPlanet’s commitment extends to developing superior disinfection and infection control solutions with an aim to boost air quality within indoor environments. Working closely with its partners, ByoPlanet develops customized solutions to meet their unique needs. Trusted by businesses and organizations around the world, including those in the sectors of animal health, hospitals, education, and government agencies, ByoPlanet’s disinfection solutions are at the forefront of creating healthier indoor spaces. ByoPlanet is a wholly-owned subsidiary of Plandai Biotechnology, Inc. For more information, visit www.byoplanet.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

About Merck Animal Health:

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

Media Contacts:

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward- looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. The information utilized to obtain the valuation was derived from unaudited financial statements and proforma projections of future earnings. These estimated valuation figures can change once the audit of the prior two fiscal years is completed and the assumptions in the projections are updated with actual figures.

SOURCE: Plandai Biotechnology